Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143288 | 1.00 | GRIK1 (0.40) | GRIK1GRIA2CYP2D6SMN1; SMN2LMNA | |
| SCHEMBL5285064 | 1.00 | GRIK1 (0.40) | GRIK1GRIA2CYP2D6SMN1; SMN2LMNA | |
| SCHEMBL9206135 | 0.89 | IDO1 (0.43) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| Hydrochloric Acid SCHEMBL8435810 | 0.88 | IDO1 (0.45) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL6949068 | 0.85 | KMT2A (0.41) | CYP2D6SMN1; SMN2LMNAMAPK1HIF1A | |
| SCHEMBL4864246 | 0.85 | KMT2A (0.40) | GRIK1GRIA2CYP2D6CYP2C19KMT2A | |
| SCHEMBL5513558 | 0.84 | HTR2C (0.43) | KMT2AEPHX1 | |
| SCHEMBL13481773 | 0.84 | CTSC (0.47) | GRIK1GRIA2CYP2D6HIF1ACYP2C19 | |
| SCHEMBL3184417 | 0.84 | CTSC (0.47) | GRIK1GRIA2CYP2D6HIF1ACYP2C19 | |
| SCHEMBL7763253 | 0.84 | CTSC (0.47) | GRIK1GRIA2CYP2D6HIF1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558246-B1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-7659305-B2 | 4-carbo- or heterocyclic alkyl-, oxy-, amino-, and thio-substituted; e.g., 2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid; controlling neurotransmitter release; uses include general treatment of pain, particularly neuropathic pain. | PFIZER INC. (US) | 2010-02-09 | — | — | US | disclosed |
| EP-1558246-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20040132801-A1 | Therapeutic proline derivatives | RAWSON DAVID JAMES (GB) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039367-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LIMITED (GN) | 2004-05-13 | — | — | WO | disclosed |
| US-5866564-A | STABILITY | SANKYO COMPANY, LIMITED (JP) | 1999-02-02 | — | — | US | disclosed |
| EP-0518558-B1 | 1-Methylcarbapenem derivatives, their preparation and their use as antibiotics | SANKYO CO (JP) | 1998-09-02 | — | — | EP | disclosed |
| US-5712267-A | Carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY,. LIMITED (JP) | 1998-01-27 | — | — | US | disclosed |
| US-5420119-A | Bactericides | SANKYO COMPANY, LIMITED (JP) | 1995-05-30 | — | — | US | disclosed |
| US-5310735-A | Carbapenem derivatives having antibiotic activity, their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 1994-05-10 | — | — | US | disclosed |
| EP-0518558-A1 | 1-Methylcarbapenem derivatives, their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132801-A1 | Therapeutic proline derivatives | PRRC2C, SLC6A7, FAAH | GRIK1 449/4885GRIA2 1499/4885CYP2D6 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.